Related references
Note: Only part of the references are listed.Myricetin ameliorates sepsis-associated acute lung injury in a murine sepsis model
Haibo Xu et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2021)
Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes
Bing-yan Liu et al.
ACTA PHARMACOLOGICA SINICA (2021)
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
Wioletta Rut et al.
NATURE CHEMICAL BIOLOGY (2021)
Screening for natural and derived bio-active compounds in preclinical and clinical studies: One of the frontlines of fighting the coronaviruses pandemic
Shaden A. M. Khalifa et al.
PHYTOMEDICINE (2021)
Crystal structure of SARS-CoV-2 papain-like protease
Xiaopan Gao et al.
ACTA PHARMACEUTICA SINICA B (2021)
The comprehensive study on the therapeutic effects of baicalein for the treatment of COVID-19 in vivo and in vitro
Junke Song et al.
BIOCHEMICAL PHARMACOLOGY (2021)
Exploration of natural compounds with anti-SARS-CoV-2 activity via inhibition of SARS-CoV-2 Mpro
Shiv Bharadwaj et al.
BRIEFINGS IN BIOINFORMATICS (2021)
Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models
Gan Wang et al.
CELL RESEARCH (2021)
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors**
Kai S. Yang et al.
CHEMMEDCHEM (2021)
Potential SARS-CoV-2 main protease inhibitors
Riddhidev Banerjee et al.
DRUG DISCOVERY TODAY (2021)
RNA-dependent RNA polymerase (RdRp) inhibitors: The current landscape and repurposing for the COVID-19 pandemic
Lei Tian et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Drug repurposing: new strategies for addressing COVID-19 outbreak
Pravin Shende et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2021)
Role of favipiravir in the treatment of COVID-19
Shashank Joshi et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like protease in vitro
Hongbo Liu et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Chinese herbal medicine: Fighting SARS-CoV-2 infection on all fronts
Zhonglei Wang et al.
JOURNAL OF ETHNOPHARMACOLOGY (2021)
Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease
Tuanjai Somboon et al.
JOURNAL OF MOLECULAR LIQUIDS (2021)
Natural Products with Potential to Treat RNA Virus Pathogens Including SARS-CoV-2
Mitchell P. Christy et al.
JOURNAL OF NATURAL PRODUCTS (2021)
Structure-Based Screening to Discover New Inhibitors for Papain-like Proteinase of SARS-CoV-2: An In Silico Study
Mostafa Jamalan et al.
JOURNAL OF PROTEOME RESEARCH (2021)
Drug repurposing approach to combating coronavirus: Potential drugs and drug targets
Jimin Xu et al.
MEDICINAL RESEARCH REVIEWS (2021)
Therapeutic targets and potential agents for the treatment of COVID-19
Yinuo Wu et al.
MEDICINAL RESEARCH REVIEWS (2021)
What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design
Muya Xiong et al.
MEDICINAL RESEARCH REVIEWS (2021)
Repurposed Antiviral Drugs for Covid-19-Interim WHO Solidarity Trial Results
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
A. C. Kalil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor ML188
Gordon J. Lockbaum et al.
VIRUSES-BASEL (2021)
Development of a Cell-Based Luciferase Complementation Assay for Identification of SARS-CoV-2 3CLpro Inhibitors
Jonathan M. O. Rawson et al.
VIRUSES-BASEL (2021)
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
Ziyang Fu et al.
NATURE COMMUNICATIONS (2021)
Mechanism of SARS-CoV-2 polymerase stalling by remdesivir
Goran Kokic et al.
NATURE COMMUNICATIONS (2021)
Modeling the Binding Mechanism of Remdesivir, Favilavir, and Ribavirin to SARS-CoV-2 RNA-Dependent RNA Polymerase
Fabian Bylehn et al.
ACS CENTRAL SCIENCE (2021)
Dual inhibition of SARS-CoV-2 and human rhinovirus with protease inhibitors in clinical development
Cheng Liu et al.
ANTIVIRAL RESEARCH (2021)
Myricetin: A review of the most recent research
Xiaominting Song et al.
BIOMEDICINE & PHARMACOTHERAPY (2021)
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
Zarir F. Udwadia et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)
Targeting SARS-CoV-2 M3CLpro by HCV NS3/4a Inhibitors: In Silico Modeling and In Vitro Screening
Anjela Manandhar et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
A Comparative Analysis of SARS-CoV-2 Antivirals Characterizes 3CLpro Inhibitor PF-00835231 as a Potential New Treatment for COVID-19
Maren de Vries et al.
JOURNAL OF VIROLOGY (2021)
The need for precision nutrition, genetic variation and resolution in Covid-19 patients
Artemis P. Simopoulos et al.
MOLECULAR ASPECTS OF MEDICINE (2021)
Detection of a SARS-CoV-2 variant of concern in South Africa
Houriiyah Tegally et al.
NATURE (2021)
Natural products in drug discovery: advances and opportunities
Atanas G. Atanasov et al.
NATURE REVIEWS DRUG DISCOVERY (2021)
Structural basis for inhibition of the SARS-CoV-2 RNA polymerase by suramin
Wanchao Yin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2021)
Structure of the SARS-CoV-2 RNA-dependent RNA polymerase in the presence of favipiravir-RTP
Katerina Naydenova et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2021)
Plitidepsin has potent preclinical efficacy against SARS-CoV-2 by targeting the host protein eEF1A
Kris M. White et al.
SCIENCE (2021)
SARS-CoV-2 M-pro inhibitors with antiviral activity in a transgenic mouse model
Jingxin Qiao et al.
SCIENCE (2021)
SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity
Seiya Ozono et al.
NATURE COMMUNICATIONS (2021)
A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication
Shin-ichiro Hattori et al.
NATURE COMMUNICATIONS (2021)
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
Jerzy Osipiuk et al.
NATURE COMMUNICATIONS (2021)
Identification of ebselen and its analogues as potent covalent inhibitors of papain-like protease from SARS-CoV-2
Ewelina Weglarz-Tomczak et al.
SCIENTIFIC REPORTS (2021)
Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
Yanmei Hu et al.
ACS INFECTIOUS DISEASES (2021)
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations
Chun-Hui Zhang et al.
ACS CENTRAL SCIENCE (2021)
Potent SARS-CoV-2 Direct-Acting Antivirals Provide an Important Complement to COVID-19 Vaccines
Stephen Pelly et al.
ACS CENTRAL SCIENCE (2021)
Elucidation of Cryptic and Allosteric Pockets within the SARS-CoV-2 Main Protease
Terra Sztain et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2021)
Phytochemical constituents, distributions and traditional usages of Arnebia euchroma: A review
Anil Kumar et al.
JOURNAL OF ETHNOPHARMACOLOGY (2021)
Clofazimine broadly inhibits coronaviruses including SARS-CoV-2
Shuofeng Yuan et al.
NATURE (2021)
X-ray screening identifies active site and allosteric inhibitors of SARS-CoV-2 main protease
Sebastian Guenther et al.
SCIENCE (2021)
Structural Insights into Plasticity and Discovery of Remdesivir Metabolite GS-441524 Binding in SARS-CoV-2 Macrodomain
Xiaomin Ni et al.
ACS MEDICINAL CHEMISTRY LETTERS (2021)
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model
Jean-Selim Driouich et al.
NATURE COMMUNICATIONS (2021)
Multiscale Simulations of SARS-CoV-2 3CL Protease Inhibition with Aldehyde Derivatives. Role of Protein and Inhibitor Conformational Changes in the Reaction Mechanism
Carlos A. Ramos-Guzman et al.
ACS CATALYSIS (2021)
Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model
C. Joaquin Caceres et al.
SCIENTIFIC REPORTS (2021)
Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode
Jian Li et al.
SCIENCE BULLETIN (2021)
In Silico Characterization of Masitinib Interaction with SARS-CoV-2 Main Protease
Ulises Martinez-Ortega et al.
CHEMMEDCHEM (2021)
Virtual high throughput screening: Potential inhibitors for SARS-CoV-2
Dhananjay Jade et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2021)
An in-silico evaluation of different bioactive molecules of tea for their inhibition potency against non structural protein-15 of SARS-CoV-2
Jatin Sharma et al.
FOOD CHEMISTRY (2021)
SARS-CoV-2 simulations go exascale to predict dramatic spike opening and cryptic pockets across the proteome
Maxwell Zimmerman et al.
NATURE CHEMISTRY (2021)
Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2
Nir Drayman et al.
SCIENCE (2021)
Identification of pyrogallol as a warhead in design of covalent inhibitors for the SARS-CoV-2 3CL protease
Haixia Su et al.
NATURE COMMUNICATIONS (2021)
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
Kangsa Amporndanai et al.
NATURE COMMUNICATIONS (2021)
Exploring Phytochemicals of Traditional Medicinal Plants Exhibiting Inhibitory Activity Against Main Protease, Spike Glycoprotein, RNA-dependent RNA Polymerase and Non-Structural Proteins of SARS-CoV-2 Through Virtual Screening
Saranya Nallusamy et al.
FRONTIERS IN PHARMACOLOGY (2021)
Remdesivir Strongly Binds to RNA-Dependent RNA Polymerase, Membrane Protein, and Main Protease of SARS-CoV-2: Indication From Molecular Modeling and Simulations
Faez Iqbal Khan et al.
FRONTIERS IN PHARMACOLOGY (2021)
Molecular Dynamics Simulations Reveal the Interaction Fingerprint of Remdesivir Triphosphate Pivotal in Allosteric Regulation of SARS-CoV-2 RdRp
Mitul Srivastava et al.
FRONTIERS IN MOLECULAR BIOSCIENCES (2021)
Natural Products, Alone or in Combination with FDA-Approved Drugs, to Treat COVID-19 and Lung Cancer
Liyan Yang et al.
BIOMEDICINES (2021)
Transcriptomic signatures and repurposing drugs for COVID-19 patients: findings of bioinformatics analyses
Guobing Li et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Dissecting nucleotide selectivity in viral RNA polymerases
Chunhong Long et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
Screening of world approved drugs against highly dynamical spike glycoprotein of SARS-CoV-2 using CaverDock and machine learning
Gaspar P. Pinto et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
dIdentification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen
Maria Kuzikov et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2021)
Resources and computational strategies to advance small molecule SARS-CoV-2 discovery: Lessons from the pandemic and preparing for future health crises
Natesh Singh et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2021)
1′-Ribose cyano substitution allows Remdesivir to effectively inhibit nucleotide addition and proofreading during SARS-CoV-2 viral RNA replication
Lu Zhang et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2021)
In silico identification of novel SARS-COV-2 2′-O-methyltransferase (nsp16) inhibitors: structure-based virtual screening, molecular dynamics simulation and MM-PBSA approaches
Mahmoud A. El Hassab et al.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY (2021)
Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics
Rick Oerlemans et al.
RSC MEDICINAL CHEMISTRY (2021)
Mechanism of inhibition of SARS-CoV-2 Mpro by N3 peptidyl Michael acceptor explained by QM/MM simulations and design of new derivatives with tunable chemical reactivity
Kemel Arafet et al.
CHEMICAL SCIENCE (2021)
Identification of SARS-CoV-2 inhibitors using lung and colonic organoids
Yuling Han et al.
NATURE (2021)
The Exploration of Chirality for Improved Druggability within the Human Kinome
Debasmita Saha et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment
Linlin Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Favipiravir, an anti-influenza drug against life-threatening RNA virus infections
Kimiyasu Shiraki et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Prophylactic and therapeutic remdesivir (GS-5734) treatment in the rhesus macaque model of MERS-CoV infection
Emmie de Wit et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV
Timothy P. Sheahan et al.
NATURE COMMUNICATIONS (2020)
Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming
Jian Chen et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
Qihui Wang et al.
CELL (2020)
An untargeted metabolomics approach to investigate the wine-processed mechanism of Scutellariae radix in acute lung injury
Lianqi Hu et al.
JOURNAL OF ETHNOPHARMACOLOGY (2020)
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Wenhao Dai et al.
SCIENCE (2020)
Structure of the RNA-dependent RNA polymerase from COVID-19 virus
Yan Gao et al.
SCIENCE (2020)
Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
Linlin Zhang et al.
SCIENCE (2020)
Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir
Wanchao Yin et al.
SCIENCE (2020)
In Silico Exploration of the Molecular Mechanism of Clinically Oriented Drugs for Possibly Inhibiting SARS-CoV-2's Main Protease
Tien Huynh et al.
JOURNAL OF PHYSICAL CHEMISTRY LETTERS (2020)
Structural and Biochemical Characterization of the nsp12-nsp7-nsp8 Core Polymerase Complex from SARS-CoV-2
Qi Peng et al.
CELL REPORTS (2020)
Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites
Sisi Kang et al.
ACTA PHARMACEUTICA SINICA B (2020)
Structure of replicating SARS-CoV-2 polymerase
Hauke S. Hillen et al.
NATURE (2020)
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Jun Lan et al.
NATURE (2020)
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Zhenming Jin et al.
NATURE (2020)
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
Zhenming Jin et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2020)
Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study
Qingxian Cai et al.
ENGINEERING (2020)
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19
Jason D. Goldman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients
Hai-xia Su et al.
ACTA PHARMACOLOGICA SINICA (2020)
Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
Shuofeng Yuan et al.
PHARMACOLOGICAL RESEARCH (2020)
Suramin Inhibits SARS-CoV-2 Infection in Cell Culture by Interfering with Early Steps of the Replication Cycle
Clarisse Salgado-Benvindo et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
Yuzhi Liu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
Chunlong Ma et al.
CELL RESEARCH (2020)
Turning the Tide: Natural Products and Natural-Product-Inspired Chemicals as Potential Counters to SARS-CoV-2 Infection
Zhonglei Wang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Unlocking COVID therapeutic targets: A structure-based rationale against SARS-CoV-2, SARS-CoV and MERS-CoV Spike
Joao Trigueiro-Louro et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
COVID-19: Drug Targets and Potential Treatments
Carmen Gil et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Repurposing Low-Molecular-Weight Drugs against the Main Protease of Severe Acute Respiratory Syndrome Coronavirus 2
Jia Gao et al.
JOURNAL OF PHYSICAL CHEMISTRY LETTERS (2020)
Michael Acceptors Tuned by the Pivotal Aromaticity of Histidine to Block COVID-19 Activity
Albert Poater
JOURNAL OF PHYSICAL CHEMISTRY LETTERS (2020)
Catalytic Asymmetric Synthesis of the anti-COVID-19 Drug Remdesivir
Mo Wang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2020)
A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19
Yohei Doi et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
Peter A. McCullough
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Protective effects and molecular mechanisms of baicalein on thioacetamide-induced toxicity in zebrafish larvae
June Zhang et al.
CHEMOSPHERE (2020)
Candidate drugs against SARS-CoV-2 and COVID-19
Dwight L. McKee et al.
PHARMACOLOGICAL RESEARCH (2020)
Mechanism and inhibition of the papain-like protease, PLpro, of SARS-CoV-2
Theresa Klemm et al.
EMBO JOURNAL (2020)
Repurposing anticancer drugs for the management of COVID-19
Khalid El Bairi et al.
EUROPEAN JOURNAL OF CANCER (2020)
3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice
Athri D. Rathnayake et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C. Yan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Structural basis of RNA cap modification by SARS-CoV-2
Thiruselvam Viswanathan et al.
NATURE COMMUNICATIONS (2020)
Structural analysis of the SARS-CoV-2 methyltransferase complex involved in RNA cap creation bound to sinefungin
Petra Krafcikova et al.
NATURE COMMUNICATIONS (2020)
Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography
Daniel W. Kneller et al.
NATURE COMMUNICATIONS (2020)
Alchemical Binding Free Energy Calculations in AMBER20: Advances and Best Practices for Drug Discovery
Tai-Sung Lee et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2020)
Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19
Robert L. Hoffman et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
The strategies and techniques of drug discovery from natural products
Li Zhang et al.
PHARMACOLOGY & THERAPEUTICS (2020)
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Christine Toelzer et al.
SCIENCE (2020)
Malleability of the SARS-CoV-2 3CL Mpro Active-Site Cavity Facilitates Binding of Clinical Antivirals
Daniel W. Kneller et al.
STRUCTURE (2020)
Identification of 14 Known Drugs as Inhibitors of the Main Protease of SARS-CoV-2
Mohammad M. Ghahremanpour et al.
ACS MEDICINAL CHEMISTRY LETTERS (2020)
Both Boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
Lifeng Fu et al.
NATURE COMMUNICATIONS (2020)
Many small steps towards a COVID-19 drug
Daniel A. Erlanson
NATURE COMMUNICATIONS (2020)
Feline coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus replication
Wayne Vuong et al.
NATURE COMMUNICATIONS (2020)
Current Prevention of COVID-19: Natural Products and Herbal Medicine
Junqing Huang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Underlying Mechanisms and Candidate Drugs for COVID-19 Based on the Connectivity Map Database
Zhonglin Li et al.
FRONTIERS IN GENETICS (2020)
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design
Wioletta Rut et al.
SCIENCE ADVANCES (2020)
Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study
Padmaja D. Wakchaure et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2020)
Targeting the RdRp of Emerging RNA Viruses: The Structure-Based Drug Design Challenge
Francesca Picarazzi et al.
MOLECULES (2020)
SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity
Lizhou Zhang et al.
NATURE COMMUNICATIONS (2020)
A Comprehensive Analysis of cis-Acting RNA Elements in the SARS-CoV-2 Genome by a Bioinformatics Approach
Firoz Ahmed et al.
FRONTIERS IN GENETICS (2020)
Chinese herbal compounds against SARS-CoV-2: Puerarin and quercetin impair the binding of viral S-protein to ACE2 receptor
Boyu Pan et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2′-O-Methyltransferase
Panupong Mahalapbutr et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
Chunlong Ma et al.
ACS PHARMACOLOGY & TRANSLATIONAL SCIENCE (2020)
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
Michael Dominic Sacco et al.
SCIENCE ADVANCES (2020)
An Overview of the Crystallized Structures of the SARS-CoV-2
Mihaela Ileana Ionescu
PROTEIN JOURNAL (2020)
GS-5734: a potentially approved drug by FDA against SARS-Cov-2
Zhonglei Wang et al.
NEW JOURNAL OF CHEMISTRY (2020)
Mutations in the SARS-CoV-2 spike RBD are responsible for stronger ACE2 binding and poor anti-SARS-CoV mAbs cross-neutralization
Masaud Shah et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2020)
Characterisation of infectious Ebola virus from the ongoing outbreak to guide response activities in the Democratic Republic of the Congo: a phylogenetic and in vitro analysis
Laura K. McMullan et al.
LANCET INFECTIOUS DISEASES (2019)
Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase
Ariane J. Brown et al.
ANTIVIRAL RESEARCH (2019)
Genomewide Analysis of Mode of Action of the S-Adenosylmethionine Analogue Sinefungin in Leishmania infantum
Arijit Bhattacharya et al.
MSYSTEMS (2019)
Strategies to diversify natural products for drug discovery
Gang Li et al.
MEDICINAL RESEARCH REVIEWS (2018)
Recombinant RNA-Dependent RNA Polymerase Complex of Ebola Virus
Egor P. Tchesnokov et al.
SCIENTIFIC REPORTS (2018)
Relative Binding Free Energy Calculations in Drug Discovery: Recent Advances and Practical Considerations
Zoe Cournia et al.
JOURNAL OF CHEMICAL INFORMATION AND MODELING (2017)
Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo(2,1-f][triazin-4-amino] Adenine C-Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses
Dustin Siegel et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Differences in anti-inflammatory effects between two specifications of Scutellariae Radix in LPS-induced macrophages in vitro
Chen Qian-Yu et al.
CHINESE JOURNAL OF NATURAL MEDICINES (2017)
Late Ebola virus relapse causing meningoencephalitis: a case report
Michael Jacobs et al.
LANCET (2016)
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys
Travis K. Warren et al.
NATURE (2016)
Accurate and Reliable Prediction of Relative Ligand Binding Potency in Prospective Drug Discovery by Way of a Modern Free-Energy Calculation Protocol and Force Field
Lingle Wang et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2015)
The re-emergence of natural products for drug discovery in the genomics era
Alan L. Harvey et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Discovery, Synthesis, And Structure-Based Optimization of a Series of N-(tert-Butyl)-2-(N-arylamido)-2-(pyridin-3-yl) Acetamides (ML188) as Potent Noncovalent Small Molecule Inhibitors of the Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) 3CL Protease
Jon Jacobs et al.
JOURNAL OF MEDICINAL CHEMISTRY (2013)
Practical synthesis of 1′-substituted Tubercidin C-nucleoside analogs
Sammy E. Metobo et al.
TETRAHEDRON LETTERS (2012)
Shikonin, a component of Chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1
X Chen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)